includ
quantit
virolog
studi
patient
fulfil
modifi
world
health
organ
definit
sar
whose
treatment
manag
unit
christian
hospit
carita
medic
centr
hong
kong
special
administr
region
china
patient
infect
either
serolog
confirm
fourfold
rise
indirect
immunofluoresc
antibodi
titer
serum
taken
admiss
within
day
symptom
onset
rtpcr
posit
sarscov
rna
confirm
clinic
specimen
die
seroconvert
day
case
definit
includ
temperatur
cough
short
breath
new
pulmonari
infiltr
shown
chest
xray
highresolut
comput
tomograph
scan
absenc
altern
diagnosi
explain
clinic
sign
symptom
treatment
protocol
clinic
manifest
progress
diseas
part
cohort
previous
report
brief
patient
prospect
monitor
diarrhea
oxygen
desatur
mechan
ventil
laboratori
evid
lymphopenia
renal
impair
liver
dysfunct
abnorm
urinalysi
first
day
death
diarrhea
defin
bowel
movement
time
per
day
consecut
day
oxygen
desatur
defin
oxygen
satur
measur
puls
oximetri
breath
room
air
patient
later
requir
mechan
ventil
hepat
dysfunct
defin
mean
level
alanin
aminotransferas
alt
alkalin
phosphatas
alp
greater
upper
limit
normal
day
day
onset
symptom
impair
renal
function
defin
serum
creatinin
level
higher
refer
rang
consecut
day
lymphopenia
defin
absolut
lymphocyt
count
consecut
day
abnorm
urinalysi
result
defin
proteinuria
mgdl
microscop
hematuria
pyuria
dipstick
test
cast
urin
combur
test
roch
diagnost
gmbh
mannheim
germani
examin
invert
microscop
experienc
technician
diagnos
sarscov
infect
npa
serum
sampl
taken
admiss
convalescentphas
serum
sampl
taken
day
symptom
onset
patient
rtpcr
sarscov
rna
perform
npa
collect
admiss
rtqpcr
perform
patient
npa
serum
stool
urin
specimen
collect
day
onset
symptom
virolog
diagnost
laboratori
test
includ
viral
cultur
rtpcr
rtqpcr
immunofluoresc
antibodi
detect
immunoglobulin
ig
g
perform
accord
previous
publish
protocol
npa
obtain
suction
nostril
pennin
mucu
extractor
pennin
healthcar
derbi
uk
mucu
specimen
trap
pennin
healthcar
cathet
connect
midway
tip
nose
auditori
meatu
rotat
continu
slowli
retriev
intermitt
suction
neg
pressur
mm
hg
procedur
repeat
nostril
secret
stuck
lumen
cathet
transfer
mucu
trap
flush
ml
viral
transport
medium
consist
earl
balanc
salt
solut
biosourc
intern
camarillo
ca
bicarbon
bovin
serum
albumin
vancomycin
amikacin
nystatin
uml
stool
suspens
made
swirl
approxim
g
stool
ml
viral
transport
medium
midstream
urin
collect
steril
contain
serum
clot
blood
collect
store
antibodi
test
rna
extract
specimen
store
rna
extract
rna
clinic
sampl
extract
use
qiaamp
viru
rna
mini
kit
qiagen
cologn
germani
instruct
manufactur
specimen
sampl
use
rna
extract
extract
rna
final
elut
rnasefre
water
store
rtqpcr
assay
rna
cdna
gener
describ
cdna
amplifi
sequenc
detect
system
appli
biosystem
foster
citi
ca
use
taqman
pcr
core
reagent
kit
appli
biosystem
typic
reaction
cdna
amplifi
reaction
contain
u
amplitaq
gold
polymeras
appli
biosystem
taqman
buffer
mmoll
dntp
mmoll
u
amperas
ung
primersprob
mixtur
assay
design
appli
biosystem
forward
primer
correspond
nt
sarscov
genom
revers
primer
correspond
nt
sequenc
report
probe
fam
tctgcgtaggcaatcc
nfq
fam
nfq
nonfluoresc
quencher
complementari
nt
reaction
first
incub
min
follow
min
reaction
thermocycl
cycl
min
plasmid
contain
target
sequenc
use
standard
control
monitor
integr
rna
extract
sampl
housekeep
gene
detect
realtim
rtpcr
two
primer
forward
revers
sampl
found
contain
detect
rna
time
data
calcul
onset
symptom
compar
viral
load
specimen
presenc
absenc
diarrhea
oxygen
desatur
mechan
ventil
lymphopenia
hepat
dysfunct
abnorm
urinalysi
find
death
rate
chisquar
fisher
exact
test
categor
variabl
mannwhitney
u
test
continu
variabl
twotail
p
valu
consid
signific
correl
number
anatom
site
detect
viral
load
rtqpcr
death
rate
calcul
linear
regress
spss
version
spss
inc
chicago
il
use
analys
sar
patient
satisfi
definit
sar
age
rang
year
mean
year
maletofemal
ratio
healthcar
worker
one
hundr
fifti
patient
ethnic
chines
filipino
follow
clinic
specimen
taken
day
individu
patient
avail
npa
n
serum
n
stool
n
urin
n
patient
laboratoryconfirm
sar
either
virolog
qualit
rtpcr
patient
npa
stool
sampl
urin
sampl
rtqpcr
patient
npa
serum
sampl
stool
sampl
urin
sampl
seroconvers
indirect
immunofluoresc
antibodi
assay
patient
six
patient
die
day
serolog
document
other
seroconvert
day
sar
confirm
rtpcr
viral
cultur
posit
sarscov
patient
npa
n
stool
n
urin
n
besid
fever
pulmonari
infiltr
shown
xray
peripher
blood
lymphopenia
common
hematolog
abnorm
admiss
afterward
tabl
admiss
day
peripher
lymphocyt
count
patient
decreas
day
peripher
lymphocyt
count
continu
decreas
patient
ultim
die
wherea
surviv
lymphocyt
count
gradual
increas
figur
seroconvers
sarscov
antibodi
also
start
around
day
diarrhea
common
extrapulmonari
clinic
manifest
day
follow
hepat
dysfunct
abnorm
urinalysi
found
patient
increas
leukocyt
esteras
pyuria
microscop
hematuria
proteinuria
none
patient
impair
renal
function
admiss
day
oxygen
desatur
develop
patient
mean
standard
deviat
sd
day
patient
die
sar
mean
sd
day
onset
symptom
four
patient
found
abnorm
mean
alp
level
admiss
day
therefor
mean
alt
level
day
analyz
correl
viral
load
mean
alt
level
admiss
day
also
analyz
howev
signific
associ
found
mean
alt
level
viral
load
differ
specimen
posit
rate
viral
load
rtqpcr
copiesml
highest
stool
specimen
follow
npa
copiesml
respect
although
viru
frequent
detect
serum
urin
mean
viral
load
specimen
copiesml
copiesml
respect
tabl
patient
lymphopenia
admiss
viru
detect
rtqpcr
npa
p
odd
ratio
confid
interv
ci
data
shown
posit
rate
viral
load
npa
significantli
correl
diarrhea
oxygen
desatur
mechan
ventil
hepat
dysfunct
death
rate
p
tabl
tabl
high
viral
load
serum
also
associ
oxygen
desatur
mechan
ventil
hepat
dysfunct
death
p
diarrhea
abnorm
urinalysi
find
stool
viral
load
associ
diarrhea
hepat
dysfunct
abnorm
urinalysi
result
death
p
higher
viral
load
urin
significantli
correl
abnorm
urinalysi
diarrhea
p
find
confirm
subgroup
analysi
patient
specimen
sampl
taken
four
site
npa
serum
stool
urin
tabl
tabl
detect
viral
load
npa
serum
associ
oxygen
desatur
ci
mechan
ventil
ci
death
ci
stool
viral
load
associ
diarrhea
ci
although
higher
viral
load
urin
longer
associ
abnorm
urinalysi
result
subgroup
analysi
patient
type
specimen
avail
analysi
antibodi
seroconvers
die
day
without
serolog
document
diagnosi
confirm
qualit
rtpcr
group
number
anatom
site
posit
rtqpcr
strongli
correl
risk
death
pearson
correl
p
death
associ
neg
rtqpcr
site
one
posit
site
risk
death
posit
two
site
posit
three
site
death
rate
increas
rtqpcr
posit
four
site
viral
load
reflect
dynam
interact
viral
replic
clearanc
bodi
defens
mechan
examin
viral
load
sar
patient
use
diagnos
monitor
progress
respons
antivir
therapi
shown
viral
load
npa
peak
around
day
rapid
decreas
concomit
normal
lymphocyt
count
rise
serum
antibodi
sarscov
figur
presenc
viru
viral
load
differ
bodi
fluid
may
also
bear
possibl
mode
transmiss
infect
day
reflect
mean
peak
viral
load
log
copiesml
log
copiesml
posit
specimen
npa
stool
respect
suggest
respiratori
droplet
indirect
contact
fece
may
import
mechan
transmiss
viral
load
typic
measur
npa
serum
admiss
diagnost
prognost
tool
viral
load
bodi
fluid
npa
serum
studi
elucid
transmiss
pathogenesi
sar
import
sarscov
respiratori
pathogen
support
strong
associ
viral
load
npa
oxygen
desatur
mechan
ventil
death
unexpectedli
viral
load
npa
also
associ
diarrhea
hepat
dysfunct
anecdot
report
use
steroid
treat
sar
tend
suggest
extrapulmonari
manifest
could
part
inflammatori
spillov
virusinduc
immun
dysfunct
excess
cytokin
activ
lung
howev
find
suggest
viral
replic
extrapulmonari
site
may
import
sinc
viral
load
stool
highli
correl
diarrhea
electron
microscopi
ileum
colon
biopsi
sar
patient
show
numer
intracellular
extracellular
viru
particl
high
viral
load
urin
also
associ
abnorm
urinalysi
find
regard
sarscov
current
known
grow
fetal
monkey
kidney
cell
ie
vero
colon
carcinoma
cell
line
correl
viral
load
stool
hepat
dysfunct
complet
unexpect
sinc
high
viral
load
stool
like
associ
signific
portal
venou
viremia
fact
viral
load
stool
also
associ
death
serum
viral
load
correl
oxygen
desatur
mechan
ventil
death
find
surpris
sinc
viremia
also
report
adenoviru
respiratori
syncyti
viru
rsv
rotaviru
infect
howev
viremia
report
shortlast
mucos
infect
one
studi
neonat
posit
rsv
antigen
nasal
wash
specimen
posit
rsv
rna
blood
high
level
adenoviru
dna
serum
also
associ
death
children
adenoviru
infect
develop
allogen
stemcel
transplant
six
children
die
adenoviru
infect
compar
patient
high
serum
level
adenovir
dna
p
lack
associ
viral
load
lymphopenia
day
explain
routin
use
steroid
induc
apoptosi
lymphocyt
appar
inferior
perform
serum
viral
load
prognost
indic
could
relat
fewer
avail
serum
sampl
cohort
howev
group
patient
oxygen
desatur
proport
significantli
differ
patient
submit
nasopharyng
sampl
day
day
compar
common
viral
respiratori
diseas
onset
peak
viral
load
nasopharynx
sar
patient
appear
delay
prospect
studi
viral
shed
nasopharyng
secret
experiment
adult
rsv
infect
measur
tissu
cultur
infect
dose
viral
titer
rtqpcr
rsv
detect
day
day
plateau
phase
day
day
peak
viral
load
copiesml
case
experiment
adult
influenza
viral
replic
npa
peak
hour
onset
symptom
declin
sharpli
thereaft
insignific
amount
viral
shed
day
peak
viru
titer
symptomat
volunt
infect
influenza
nasopharyng
wash
viral
load
posit
correl
symptom
fever
malais
well
amount
viral
shed
howev
report
low
incid
viremia
earli
peak
nasopharyng
viral
load
two
condit
could
explain
inher
characterist
viral
replic
background
igg
iga
crossreact
homolog
antigen
previou
infect
innat
immun
host
mani
experiment
infect
profil
viral
load
npa
document
volunt
adult
lowlevel
background
antibodi
concomit
cellmedi
immun
influenza
rsv
fals
neg
serum
viral
load
influenza
rsv
infect
could
relat
hemagglutin
properti
two
virus
may
remain
stuck
erythrocyt
clot
blood
sampl
novel
emerg
infecti
diseas
sar
gener
popul
would
background
partial
immun
viremia
delay
peak
viral
load
day
npa
therefor
complet
unexpect
one
limit
present
studi
retrospect
natur
specimen
provid
approxim
day
could
test
analyz
chang
lymphocyt
subset
also
analyz
nonetheless
lymphocyt
chang
sar
patient
well
report
two
group
show
consist
decreas
peripher
blood
level
dendrit
cell
subset
natur
killer
cell
lymphocyt
b
lymphocyt
sar
predominantli
respiratori
infect
possibl
spread
mucos
lumen
bloodstream
extrapulmonari
site
viral
replic
lead
nonrespiratori
manifest
concomit
immun
dysregul
associ
inflammatori
damag
could
accentu
diseas
progress
death
high
viral
load
npa
without
high
viral
load
serum
use
prognost
indic
respiratori
failur
death
presenc
viral
rna
multipl
bodi
site
also
indic
poor
prognosi
earli
treatment
effect
antivir
agent
day
may
decreas
peak
viral
load
amelior
symptom
improv
outcom
earli
treatment
may
also
reduc
viral
shed
thu
risk
transmiss
